limb-girdle muscular dystrophyTrials & approvals
The FDA has accepted BridgeBio's application for BBP-418, potentially the first drug for limb-girdle muscular dystrophy, marking a significant advancement in the muscular dystrophy treatment landscape. This priority review reflects the growing momentum in developing therapies for this rare disease.
The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly building momentum in muscular dystrophy more broadly.
Original title: “FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug”